NOVALIQ AND BLP MANAGEMENT GROUP ESTABLISHED NEW COMPANY, BETALIQ INC., TO LEVERAGE EYESOL TECHNOLOGY TO TREAT GLAUCOMA
- Betaliq is developing ophthalmic ß-blockers for the treatment of glaucoma using Novaliq’s waterfree EyeSol® technology
- Betaliq successfully collected proceeds in a Series A round
Novaliq GmbH, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol® and BLP Management group today announce the formation and funding of Betaliq Inc., a new company located in Tampa, Florida.